Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-12 4:28 pm Unchanged |
2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% |
0 (Unchanged) |
Filing History |
| 2025-03-07 6:15 pm Sale |
2025-03-05 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 19,260,971 10.100% |
-6,000,000 (-23.75%) |
Filing History |
| 2025-02-13 5:23 pm Purchase |
2024-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
Kumar Neil | 10,466,712 5.410% |
507,208 (+5.09%) |
Filing History |
| 2025-01-31 7:18 pm Sale |
2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% |
-3,065,616 (-12.20%) |
Filing History |
| 2024-11-12 11:44 am Unchanged |
2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
12,878,839 6.800% |
0 (Unchanged) |
Filing History |
| 2024-11-06 5:04 pm Unchanged |
2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% |
0 (Unchanged) |
Filing History |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
12,878,839 6.800% |
2,722,066 (+26.80%) |
Filing History |
| 2024-09-17 6:41 pm Sale |
2024-09-13 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 25,260,971 13.400% |
-5,800,000 (-18.67%) |
Filing History |
| 2024-08-20 8:42 pm Unchanged |
2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% |
0 (Unchanged) |
Filing History |
| 2024-02-16 7:15 pm Purchase |
2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
Kumar Neil | 9,959,504 5.590% |
135,596 (+1.38%) |
Filing History |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | BridgeBio Pharma, Inc. BBIO |
The Vanguard Group | 12,800,294 7.360% |
2,208,839 (+20.85%) |
Filing History |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
10,156,773 5.800% |
322,372 (+3.28%) |
Filing History |
| 2024-01-23 10:16 am Sale |
2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
STATE STREET CORP STT |
5,086,899 2.920% |
-3,758,044 (-42.49%) |
Filing History |
| 2023-11-22 4:15 pm Unchanged |
2023-07-18 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 15.700% |
0 (Unchanged) |
Filing History |
| 2023-07-19 9:52 pm Sale |
2023-07-18 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 15.700% |
-1,500,000 (-5.63%) |
Filing History |
| 2023-02-14 4:18 pm Purchase |
2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
Kumar Neil | 9,823,908 6.420% |
820,697 (+9.12%) |
Filing History |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | BridgeBio Pharma, Inc. BBIO |
The Vanguard Group | 10,591,455 7.090% |
1,259,772 (+13.50%) |
Filing History |
| 2023-02-08 10:30 am Purchase |
2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
STATE STREET CORP STT |
8,844,943 5.920% |
8,844,943 (New Position) |
Filing History |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
9,834,401 6.600% |
558,811 (+6.02%) |
Filing History |
| 2022-02-14 9:01 pm Purchase |
2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
PERCEPTIVE ADVISORS LLC | 7,128,755 4.800% |
422,487 (+6.30%) |
Filing History |